CNS Pharmaceuticals (CNSP)
NASDAQ:CNSP
US Market
Holding CNSP?
Track your performance easily

CNS Pharmaceuticals (CNSP) Income Statement

905 Followers

CNS Pharmaceuticals Income Statement

Last quarter (Q2 2024), CNS Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, CNS Pharmaceuticals's net income was $-2.53M. See CNS Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.90M$ 18.87M$ 15.27M$ 14.49M$ 9.45M$ -3.83M
Operating Income
$ -15.99M$ -18.87M$ -15.27M$ -14.49M$ -9.45M$ -3.85M
Net Non Operating Interest Income Expense
$ -11.42K$ -13.88K$ -7.03K$ -9.29K$ -3.26K$ -26.15K
Other Income Expense
$ -1.84K-----
Pretax Income
$ -8.88M$ -18.85M$ -15.27M$ -14.50M$ -9.46M$ -3.88M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -15.97M$ -18.85M$ -15.27M$ -14.50M$ -9.46M$ -3.88M
Basic EPS
$ -27.25$ -0.10$ -11.22$ -15.90$ -17.10-
Diluted EPS
$ -27.25$ -0.10$ -11.22$ -15.90$ -17.10$ -8.40
Basic Average Shares
$ 9.67M$ 3.77M$ 1.36M$ 878.44K$ 553.95K$ 454.93K
Diluted Average Shares
$ 9.67M$ 3.77M$ 1.36M$ 878.44K$ 553.95K$ 461.57K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 8.90M$ 18.87M$ 15.27M$ 14.49M$ 9.45M$ -3.83M
Net Income From Continuing And Discontinued Operation
$ -15.97M$ -18.85M$ -15.27M$ -14.50M$ -9.46M$ -3.88M
Normalized Income
$ -10.22M$ -14.79M-$ -11.45M--
Interest Expense
------
EBIT
$ -8.87M$ -18.84M$ -15.27M$ -14.49M$ -9.45M$ -3.85M
EBITDA
$ -8.87M$ -18.83M$ -15.26M$ -14.47M$ -9.44M$ -3.73M
Currency in USD

CNS Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis